Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.23 and traded as high as $3.89. Sonoma Pharmaceuticals shares last traded at $3.30, with a volume of 206,121 shares trading hands.
Sonoma Pharmaceuticals Stock Up 3.5 %
The company has a fifty day moving average of $0.02 and a 200-day moving average of $0.01.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported $0.00 earnings per share for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 65.66% and a negative net margin of 35.91%. The business had revenue of $3.39 million for the quarter. Equities research analysts anticipate that Sonoma Pharmaceuticals, Inc. will post -4 earnings per share for the current year.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Read More
- Five stocks we like better than Sonoma Pharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- The Significance of Brokerage Rankings in Stock Selection
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.